Short Interest in Enfusion, Inc. (NYSE:ENFN) Decreases By 22.4%

Enfusion, Inc. (NYSE:ENFN) was the target of a large decline in short interest in October. As of October 31st, there was short interest totalling 1,180,000 shares, a decline of 22.4% from the October 15th total of 1,520,000 shares. Currently, 2.4% of the company’s stock are short sold. Based on an average daily trading volume, of 381,300 shares, the days-to-cover ratio is presently 3.1 days.

Enfusion Stock Down 0.9 %

Shares of NYSE:ENFN traded down $0.09 on Friday, reaching $9.79. The company had a trading volume of 668,885 shares, compared to its average volume of 477,284. The stock has a market capitalization of $1.26 billion, a P/E ratio of 244.81, a P/E/G ratio of 3.66 and a beta of 0.93. The stock has a 50-day moving average price of $9.00 and a 200 day moving average price of $8.86. Enfusion has a twelve month low of $7.52 and a twelve month high of $10.45.

Institutional Trading of Enfusion

Several hedge funds and other institutional investors have recently bought and sold shares of ENFN. Vanguard Group Inc. lifted its position in Enfusion by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 3,653,189 shares of the company’s stock worth $33,792,000 after buying an additional 51,670 shares in the last quarter. Geode Capital Management LLC raised its stake in Enfusion by 7.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,029,366 shares of the company’s stock worth $9,770,000 after buying an additional 70,367 shares during the period. Wellington Management Group LLP lifted its holdings in shares of Enfusion by 6.7% during the 3rd quarter. Wellington Management Group LLP now owns 976,296 shares of the company’s stock valued at $9,265,000 after purchasing an additional 61,032 shares in the last quarter. State Street Corp increased its position in shares of Enfusion by 2.3% during the third quarter. State Street Corp now owns 952,895 shares of the company’s stock worth $9,043,000 after acquiring an additional 21,729 shares in the last quarter. Finally, Impax Asset Management Group plc lifted its holdings in shares of Enfusion by 25.4% in the third quarter. Impax Asset Management Group plc now owns 676,948 shares of the company’s stock valued at $6,424,000 after purchasing an additional 136,948 shares in the last quarter. 81.05% of the stock is currently owned by institutional investors and hedge funds.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.